Biotechnology
WuXi AppTec Receives Frost & Sullivan's 2025 Global Company of the Year Recognition in the CRDMO Industry
WuXi AppTec sets new benchmarks in strategic execution and technological
advancement, further strengthening its ability to support innovators worldwide
as they deliver breakthrough medicines for patients.
SAN ANTONIO, Nov. 20, 2025 /PRNewswire/ -- Frost & Sullivan
2025-11-20 10:00
707
BIOVOZ and the University of Auckland Join Forces to Lead the Next Frontier in Anti-Aging Research
From Ingredient Supplementation to Gene Regulation: BIOVOZ and the University of Auckland Pioneer a New Era in Beauty Science AUCKLAND, New Zealand, Nov. 19, 2025 /PRNewswire/ -- Leading beauty brand BIOVOZ has announced a strategic research partnership with the University ofAuckland, marking a ...
2025-11-19 15:02
548
Lynk Pharmaceuticals Announces Key Phase II Clinical Results of LNK01004 for the Treatment of Patients with Moderate-to-Severe Atopic Dermatitis
HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restric...
2025-11-19 08:00
882
CRScube acquires Mednet to expand global eClinical capabilities
SEOUL, South Korea and MINNEAPOLIS, Nov. 18, 2025 /PRNewswire/ -- CRScube has announced the successful acquisition of Mednet, marking a key milestone in its global strategic growth and expansion into the North American market. The transaction unites two respected eClinical technology vendors with...
2025-11-18 17:00
864
INSTITUTE OF NEURODIVERSITY, NEUROPOWER WORLD, AND SINGAPORE BRINGS NEURODESIGN TO THE FOREFRONT OF SINGAPORE'S URBAN PLANNING
Hazleen Ahmad, Founder of Neuropower World and Chair & Founder of ION Singapore, to launch pilot projects and training programmes embedding neurodesign into workplaces, housing, parks, and transport hubs SINGAPORE, Nov. 18, 2025 /PRNewswire/ -- The Institute of Neurodiversity (ION) Singapore and ...
2025-11-18 09:00
732
Ajinomoto Bio-Pharma Services Wins "Best ADC Preclinical Publication 2024" Award for AJICAP® Technology at 2025 World ADC Awards
Recognition underscores Ajinomoto Bio-Pharma Services' innovation and scientific excellence in advancing next-generation antibody-drug conjugate technologies TOKYO, Nov. 17, 2025 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract de...
2025-11-17 22:26
865
Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US
SHANGHAI and JERSEY CITY, N.J., Nov. 17, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection...
2025-11-17 22:06
1102
AI and Multi-omics are Transforming Cancer Care: APAC Precision Oncology Conference Outlines the Future of Early Detection and Personalized Treatment
HONG KONG, Nov. 17, 2025 /PRNewswire/ -- The APAC Precision Oncology Conference
2025
2025-11-17 13:45
784
Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine
* Lundbeck's new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan's Ministry of Health, Labor and Welfare (MHLW), marking a significant step forward towards expanding access to the novel preventive migraine treatment for patients acrossJapan * Similar marketing authorization...
2025-11-14 17:43
764
Amorepacific Named CES Innovation Award Honoree for Advanced Electronic Skin Platform
- Co-developed by Amorepacific and MIT, Skinsight™ receives recognition as the company's seventh consecutive win at CES - Applied in substantiating the efficacy of a Sulwhasoo product, with functionality in skin-aging analytics backed by published research SEOUL, South Korea, Nov. 14, 2025 /PR...
2025-11-14 09:00
815
Fosun International Receives "ESG & Corporate Sustainability Excellence Award" from Hong Kong Economic Journal
HONG KONG, Nov. 14, 2025 /PRNewswire/ -- On 13 November 2025, Hong Kong Economic Journal (HKEJ), Hong Kong's first Chinese-language financial newspaper, hosted the "ESG & Sustainability Awards of Excellence 2025" ceremony. At the event, Fosun International received the "ESG & Corporate Sustainab...
2025-11-14 09:00
2357
KHB Showcases the Enhanced FOCUS PEGASUS MF200 -- Redefining Efficiency in Veterinary Diagnostics
XI'AN, China, Nov. 13, 2025 /PRNewswire/ -- Guangzhou Focus Biotechnology Co., Ltd., a subsidiary of KHB Group and an innovator in veterinary point-of-care testing (POCT) solutions, presents the enhanced FOCUS PEGASUS MF200 Automatic Multifunctional Veterinary Analyzer — a next-generation system ...
2025-11-13 15:18
752
EirGenix Signed The Commercial Licensinse Agreement for It's Second HER2 Biosimilar Asset EG1206A
TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast cancer biosim...
2025-11-12 16:12
816
/C O R R E C T I O N -- Heng Ren Partners/
In the news release, Independent Sinovac Shareholders Express Strong Support for Immediate Dividend Payment, issuedNov. 11, 2025 by Heng Ren Partners over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at th...
2025-11-12 12:31
2454
Alpha IVF Singapore uses Advanced Fertility Genomic Screening and Artificial Intelligence Embryo Scoring to help couples become parents
SINGAPORE, Nov. 12, 2025 /PRNewswire/ -- In-vitro fertilisation (IVF) has become increasingly prominent due to societal shifts towards delayed childbearing, infertility issues, and advances in medical technology that have improved success rates. At Alpha IVF Singapore, Advanced Fertility Genomic ...
2025-11-12 10:00
711
OPALESCENCE Trial Published in EJNMMI: Confirms Theranostic Potential of TLX250-CDx in Breast Cancer
MELBOURNE, Australia and INDIANAPOLIS, Nov. 12, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that final positive results from the Phase 2 OPALESCENCE trial[1] of TLX250-CDx (89 Zr-girentuximab) in metastatic triple negative breast cancer (mTNB...
2025-11-12 04:00
1160
Lundbeck delivers 14% CER revenue growth, reflecting stronger momentum from Vyepti® and Rexulti® driven by additional investments
VALBY, Denmark, Nov. 12, 2025 /PRNewswire/ -- Key highlights Lundbeck's total revenue grew by +14% CER[1] (+13% DKK) to DKK 18,537 million in the first nine months of 2025. Growth in the U.S. andEurope was the driver of this strong performance. * United States: DKK 9,955 million (+22% CER; +19...
2025-11-12 03:11
993
SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine
BOSTON and SAN DIEGO, Nov. 11, 2025 /PRNewswire/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at theAssociation for Molecular Pa...
2025-11-11 21:01
821
Guo Guangchang: Fosun Strengthens Globalization Capabilities, Accelerates Innovation through Open Cooperation
HONG KONG, Nov. 11, 2025 /PRNewswire/ -- On 8 November, Guo Guangchang, Chairman of Fosun International, attended the 3rd Pujiang Biopharmaceutical Original Innovation Conference 2025. During the conference, Guo Guangchang stated, "At this crucial juncture today,China's pharmaceutical innovation ...
2025-11-11 15:41
1946
Brii Biosciences Presents Late-Breaking Data from Ongoing Phase 2 ENSURE Study at AASLD 2025, Reinforcing BRII-179's Potential as a Curative Treatment for Chronic Hepatitis B
* Cohort 4 follow-up confirms durable hepatitis B surface antigen (HBsAg) loss at 24 weeks post end of treatment (EOT) in BRII-179 anti-HBs responders treated with elebsiran plus pegylated interferon alfa (PEG-IFNα) * Data suggest the potential to shorten PEG-IFNα treatment duration for BRII-...
2025-11-10 21:30
2003
Week's Top Stories
Most Reposted
SGTraDex and IMDA Receive Pro-Enterprise Impact & Partnership Award for Interoperable Digital Documents Against Payment Trade Cooperation
[Picked up by 313 media titles]
2025-11-25 15:37
Senetas and Nokia Announce Strategic Alliance to Secure Mission-Critical Networks for Defence and Government
[Picked up by 311 media titles]
2025-11-27 07:25SpeQtre, the entanglement-based quantum comms demonstrator satellite, is now on orbit
[Picked up by 291 media titles]
2025-11-29 09:00
HOTEL GROOVE SHINJUKU strengthens its services for deaf and hard of hearing guests
[Picked up by 289 media titles]
2025-11-25 10:00
Pop the 90s: The Westin Surabaya and Four Points Pakuwon Indah Welcomes 2026 with a Spectacular Live Show Featuring Project Pop
[Picked up by 285 media titles]
2025-11-26 10:49
Most Read
LightInTheBox to Hold 2025 Annual General Meeting on December 19, 2025
2025-11-25 21:20
2666
MINISO Unveils Australia's First and Largest MINISO LAND Flagship at Sydney Chatswood
2025-11-27 18:56
2180
